In-line Filters on ICU

February 28, 2019 updated by: Professor Kai Zacharowski, M.D., Ph.D., FRCA, Johann Wolfgang Goethe University Hospital
The purpose of this study is to determine whether the use of 0.2/1.2 microliter in-line filter reduces the incidence of severe vasoplegia comparing to the 5 microliter filter.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

3281

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All patients, which will be treated on the anaesthesiological/surgical ICU of the University Hospital Frankfurt between 2013 - 2014

Description

Inclusion Criteria:

  • all patients

Exclusion Criteria:

  • Younger than 18 years

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
0.2/1.2 microliter filter
Use of 0.2/1.2 microliter filters for intravenous drug administration
5 mircroliter filter
Use of 5 microliter filters for intravenous drug administration

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Incidence of severe vasoplegia
Time Frame: participants will be followed for the duration of intensive care unit stay, an expected average of 1 week
participants will be followed for the duration of intensive care unit stay, an expected average of 1 week

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Organ dysfunction
Time Frame: participants will be followed for the duration of intensive care unit stay, an expected average of 1 week
Severity of organdysfunction (SOFA-Score), incidence and severity of respiratory failure (Horovitz- Index), incidence and severity of acute kidney failure (RIFLE criteria), incidence and severity of delirium
participants will be followed for the duration of intensive care unit stay, an expected average of 1 week
Inflammation
Time Frame: participants will be followed for the duration of intensive care unit stay, an expected average of 1 week
Interleukin-6
participants will be followed for the duration of intensive care unit stay, an expected average of 1 week
Duration of ICU and hospital stay
Time Frame: participants will be followed for the duration of intensive care unit/ hospital stay, an expected average of 1 or 4 week (s), respectively
participants will be followed for the duration of intensive care unit/ hospital stay, an expected average of 1 or 4 week (s), respectively
In-hospital mortality
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 4 weeks
participants will be followed for the duration of hospital stay, an expected average of 4 weeks
Morbidity
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 4 weeks
Incidence of preoperative myocardial infarction, stroke, pneumonia, sepsis and acute kidney failure according to routine documentation
participants will be followed for the duration of hospital stay, an expected average of 4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Kai Zacharowski, M.D., University Hospital Frankfurt. Department of Anesthesiology, Intensive-Care Medicine and Pain Therapy.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2013

Primary Completion (Actual)

January 1, 2016

Study Completion (Actual)

December 1, 2018

Study Registration Dates

First Submitted

October 29, 2014

First Submitted That Met QC Criteria

October 30, 2014

First Posted (Estimate)

November 2, 2014

Study Record Updates

Last Update Posted (Actual)

March 1, 2019

Last Update Submitted That Met QC Criteria

February 28, 2019

Last Verified

February 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • In-line Filter 13/14

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Micropore Filters

Subscribe